17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF(V600E) inhibitors in melanoma cells of different genetic subtypes

Similar Items

• Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
  od: Hartman, Mariusz L., i dr.
  Izdano: (2020)
• Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of (V600E)BRAF melanoma cells and their response to vemurafenib and trametinib in vitro
  od: Zalesna, Izabela, i dr.
  Izdano: (2017)
• 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines
  od: Mariusz L. Hartman, i dr.
  Izdano: (2020-05-01)
• 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines
  od: Hartman, Mariusz L., i dr.
  Izdano: (2020)
• TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF(V600E) melanoma cells
  od: Hartman, Mariusz L., i dr.
  Izdano: (2019)